Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
VPL vs XBI: how they differ
VPL and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Vanguard Pacific Stock Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VPL and XBI hold 0% of their money in the same securities at the same weight.
| Only in VPL | Only in XBI |
|---|---|
| Samsung Electronics Co Ltd 6.06% | Apogee Therapeutics Inc 1.49% |
| SK hynix Inc 4.12% | Moderna Inc 1.41% |
| Commonwealth Bank of Australia 1.80% | Twist Bioscience Corp 1.41% |
| Toyota Motor Corp 1.74% | Oruka Therapeutics Inc 1.38% |
| Mitsubishi UFJ Financial Group Inc 1.69% | Kymera Therapeutics Inc 1.36% |
| BHP Group Ltd 1.66% | Viking Therapeutics Inc 1.31% |
| Hitachi Ltd 1.18% | Praxis Precision Medicines Inc 1.29% |
| Advantest Corp 1.16% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| VPL Vanguard Pacific Stock Index Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | State Street |
| What it is | Pacific Stock | SPDR S&P Biotech |
| Total return, 1 year | +36.9% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +19.4 pts | +46.5 pts |
| Expense ratio | 0.07% | 0.35% |
| Already in the S&P 500 | 0.1% | 8.5% |
| Holdings | 2335 | 150 |
VPL in plain words
VPL is an index equity fund tracking the Pacific Stock. Over the year to Sep 11, 2026 it returned +36.9% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.07% a year. By its holdings filed for Apr 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 2335 positions, with the top ten at 21.6%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VPL or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, VPL returned +36.9% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VPL or XBI?
- VPL charges 0.07% a year and XBI charges 0.35%, so VPL is cheaper. Fees come from each fund's prospectus.
- How much do VPL and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of VPL and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VPL against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/VPL-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources